New eczema ointment shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 65 years at screening. * Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for at least 3 months at screening. * Stable course of AD (not spontaneously improving or rapidly deteriorating) as determined by the investigator in the 3 weeks before screening. * IGA score of 3 to 4 at screening and baseline. * BSA of AD involvement, excluding the Scalp, Palms, and Soles, of 5% to 35% at screening and baseline. * Willingness to avoid pregnancy or fathering children based on the criteria as outlined in the protocol. Exclusion Criteria: * Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would pose a significant risk to the participant or interfere with the interpretation of study data. * Concurrent conditions and history of: * Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Baseline. * Active acute bacterial, fungal, or viral skin infection within 1 week before Baseline. * Any other concomitant skin disorder, pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesion. * Any other concomitant non-skin disorder with the treatment that may interfere with the evaluation of AD. * Use of any of the following treatments within the indicated period before Baseline: * 6 weeks: Dupilumab * 5 half-lives or 12 weeks, whichever is longer: biologic agents (except dupilumab). * 4 weeks: Janus kinase (JAK) inhibitors. * 5 half-lives or 4 weeks, whichever is longer: Systemic therapy for AD, including but not limited to corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE4)-inhibitors, Ultraviolet (UV) light therapy, or traditional Chinese medicine. * 2 weeks: Sedating antihistamines. * 1 week: Topical AD treatments (except topical emollient treatments), including but not limited to TCS, TCIs, or topical PDE-4 inhibitors. * Hepatitis B surface antigen (HBs Ag) positive (+); HCV ribonucleic acid (RNA) detectable in any subject with anti-HCV antibody (HCV Ab); Human immunodeficiency virus (HIV) positive (+). * Participants with the following hematologic abnormalities at screening: * ALT or AST ≥ 2 × ULN * TBiL ≥ 2 × ULN * Creatinine ≥ 1.5 × ULN * History of alcoholism or drug addiction within 6 months before screening or current alcohol or drug use. * Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before Baseline with another investigational medication or current enrollment in another investigational drug protocol. * Participants who are pregnant, nursing, or planning a pregnancy during the study period. * Participants with known allergies to components or excipients of the test drug.